virtual
antivir
drug
avail
treatment
infect
rna
virus
particularli
worrisom
sinc
highli
pathogen
emerg
virus
like
continu
rna
virus
virus
caus
acut
sever
ill
includ
sever
respiratori
diseas
hemorrhag
fever
enceph
high
case
fatal
rate
import
potent
safe
drug
hand
use
treatment
prophylaxi
infect
drug
approv
treatment
rna
viru
infect
hiv
influenza
channel
inhibitor
amantadin
rimantadin
influenza
neuraminidas
inhibitor
oseltamivir
zanamivir
ribavirin
treatment
infect
respiratori
syncyti
viru
hepat
c
viru
molecular
mechan
ribavirin
inhibit
viral
replic
deplet
intracellular
gtp
pool
induct
error
catastroph
may
readili
allow
design
analogu
potentselect
parent
drug
highli
pathogen
rna
virus
belong
varieti
viru
famili
particular
replic
strategi
thu
offer
wealth
potenti
target
select
inhibit
viral
replic
provid
nonexhaust
review
potenti
experiment
strategi
use
small
molecul
inhibit
replic
sever
rna
virus
approach
use
interferon
hostrespons
modifi
immun
serum
neutral
antibodi
address
review
paper
one
three
introduc
special
issu
antivir
research
describ
potenti
antivir
drug
strategi
may
employ
treat
prevent
infect
highli
pathogen
rna
virus
second
articl
review
epidemiolog
pathogenesi
repres
diseas
third
discuss
experiment
sequencebas
approach
therapi
bray
spurger
et
al
two
paper
issu
cover
anim
model
hemorrhag
fever
enceph
caus
highli
pathogen
rna
virus
other
describ
opportun
research
support
collabor
focu
treatment
specif
diseas
see
highli
pathogen
rna
virus
belong
variou
viru
famili
includ
arenavirida
lassa
argentin
hemorrhag
fever
ahf
virus
bunyavirida
crimean
correspond
author
fax
email
address
johanneyt
regakuleuvenb
j
neyt
congo
hemorrhag
fever
cchf
viru
hantavirus
coronavirida
sever
acut
respiratori
syndrom
sar
coronaviru
filovirida
marburg
ebola
viru
flavivirida
yellow
fever
viru
japanes
enceph
viru
flavivirus
caus
enceph
paramyxovirida
nipah
hendra
viru
orthomyxovirida
influenza
togavirida
chikungunya
western
eastern
venezuelan
equin
enceph
virus
addit
pathogen
seriou
threat
human
health
virus
footandmouth
diseas
viru
picornavirida
classic
swine
fever
viru
flavivirida
threat
livestock
enorm
impact
economi
review
gori
et
al
present
antivir
drug
formal
licens
use
human
mostli
treatment
infect
human
immunodefici
viru
hiv
hepat
b
viru
hbv
herpesvirus
number
licens
antivir
drug
use
treatment
highli
pathogen
rna
viru
infect
limit
influenza
channel
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
ribavirin
licens
treatment
respiratori
syncyti
viru
rsv
see
front
matter
elsevi
bv
right
reserv
hepat
c
viru
hcv
infect
also
use
treatment
lassa
fever
thu
unmet
need
potent
inhibitor
rna
viru
replic
broad
spectrum
possibl
first
discuss
use
licens
antivir
drug
treatment
infect
caus
highli
pathogen
rna
virus
next
provid
nonexhaust
review
potenti
target
inhibit
replic
rna
virus
market
drug
treatment
prophylaxi
infect
highli
pathogen
rna
virus
rather
limit
drug
brought
market
influenza
caus
worldwid
epidem
signific
morbid
mortal
except
rule
see
paper
beigel
bray
infect
influenza
viru
channel
inhibitor
amantadin
rimantadin
neuraminidas
inhibitor
oseltamivir
zanamivir
formal
licens
first
synthet
compound
shown
inhibit
influenza
replic
amantadin
fig
compound
block
migrat
h
ion
via
viral
ion
channel
interior
viru
particl
resid
endosom
davi
et
al
acidif
interior
viral
particl
result
destabil
capsid
result
uncoat
amantadin
prevent
acidif
process
thu
uncoat
horimoto
kawaoka
de
clercq
channel
inhibitor
howev
effect
influenza
strain
resist
drug
develop
readili
monto
recent
year
dramat
increas
preval
amantadineresist
influenza
viru
strain
season
influenza
avian
influenza
extens
use
amantadin
poultri
farm
asia
may
one
reason
high
amantadineresist
incid
bright
et
al
et
al
mechan
influenza
viru
releas
host
cell
viral
neuraminidas
extens
document
bud
host
cell
viral
hemagglutinin
interact
host
cell
receptor
glycoprotein
bear
n
acetylneuramin
acid
nana
neuraminidas
cleav
nana
cellsurfac
glycoprotein
specif
bond
sialic
acid
link
galactos
alfa
alfa
linkag
enabl
progeni
viru
leav
infect
cell
spread
host
cell
inhibit
neuraminidas
prevent
viru
releas
thu
spread
viru
moscona
b
neuraminidas
inhibitor
design
follow
similar
transitionst
principl
abdelmagid
et
al
appli
peptidomimet
hiv
proteas
inhibitor
provid
influenza
inhibitor
dana
acid
fig
fana
acid
fig
ration
design
led
develop
neuraminidas
inhibitor
zanamivir
fig
oseltamivir
fig
von
itzstein
et
al
kim
et
al
compound
highli
potent
inhibitor
influenza
neuraminidas
influenza
b
viru
replic
vitro
vivo
mice
ferret
prophylact
therapeut
effect
influenza
human
review
de
clercq
mutat
may
engend
resist
influenza
influenza
oseltamivir
zanamivir
neuraminidas
tyrosin
posit
involv
network
hydrogen
bond
histidin
posit
russel
et
al
insight
structur
type
neuraminidas
suggest
new
opportun
futur
design
new
neuraminidas
inhibitor
russel
et
al
peramivir
fig
cyclopentan
neuramidinas
inhibitor
like
oseltamivir
zanamivir
act
sialic
acid
analogu
transitionst
intermedi
neuraminidas
activ
site
develop
peramivir
support
us
depart
health
human
servic
http
inject
version
peramivir
develop
also
case
zanamivir
see
also
beigel
bray
avail
inject
neuraminidas
inhibitor
may
import
asset
treat
patient
hospit
sever
potenti
lifethreaten
influenza
inject
formul
may
ensur
appropri
dose
may
concern
oral
inhal
antiinfluenza
agent
fig
broadspectrum
inhibitor
rna
viru
replic
formal
approv
treat
hcv
infect
combin
pegyl
interferon
aerosol
form
treatment
pediatr
rsv
infect
drug
also
use
experiment
number
condit
includ
lassa
fever
see
khan
et
al
cchf
viru
ergonul
hantavirus
jonsson
et
al
synthesi
antivir
activ
ribavirin
first
report
earli
compound
found
inhibit
replic
number
virus
almost
rna
virus
vitro
shown
exert
protect
effect
experiment
anim
model
huffman
et
al
ribavirin
sinc
shown
inhibit
vitro
replic
virtual
rna
viru
studi
although
potenc
may
vari
consider
depend
natur
viru
graci
cameron
although
almost
rna
virus
sensit
vitro
antivir
activ
ribavirin
virus
suscept
other
overal
ribavirin
potent
antivir
drug
effect
concentr
ec
valu
mostli
well
particular
replic
rsv
rel
effici
inhibit
ribavirin
virus
sever
picornaflavi
filovirida
less
suscept
drug
ribavirin
report
inhibit
replic
sever
arenavirus
includ
lassa
viru
cell
cultur
huggin
et
al
mckee
et
al
andrei
de
clercq
gunther
et
al
benefici
effect
experiment
anim
model
lassa
fever
stephen
jahrl
jahrl
et
al
dvoretskaia
et
al
vitro
antivir
activ
ribavirin
also
demonstr
bunyavirus
includ
cchf
viru
rift
valley
fever
viru
hantavirus
watt
et
al
huggin
severson
et
al
ribavirin
inhibit
replic
coronaviru
includ
sarscoronaviru
saijo
et
al
barnard
et
al
flavivirus
neyt
et
al
shown
efficaci
experiment
infect
anim
virus
likewis
ribavirin
effect
anim
model
filoviru
infect
huggin
like
paramyxovirus
rsv
nipah
viru
rel
sensit
ribavirin
cell
cultur
limit
efficaci
compound
demonstr
anim
model
snell
georgescourbot
et
al
ribavirin
also
shown
inhibit
vitro
replic
alphavirus
chikungunya
equin
enceph
virus
briolant
et
al
markland
et
al
despit
fact
antivir
activ
ribavirin
report
year
ago
molecular
mechan
compound
exert
antivir
activ
still
remain
matter
debat
inosin
monophosph
imp
dehydrogenas
cellular
enzym
convert
imp
xanthosin
monophosph
de
novo
synthesi
pathway
guanosin
monophosph
gmp
inhibit
ribavirin
monophosph
streeter
et
al
fig
subsequ
deplet
intracellular
gtppool
compromis
suppli
nucleotid
synthesi
progeni
viral
rna
mechan
provid
reason
explan
broadspectrum
antirna
viru
activ
ribavirin
streeter
et
al
ribavirinresist
sindbi
viru
shown
carri
mutat
viral
guanylyltransferas
gene
line
observ
drugresist
sindbi
viru
replic
rel
effici
cell
low
intracellular
gtp
concentr
either
induc
ribavirin
imp
dehydrogenas
inhibitor
malinoski
stollar
scheidel
stollar
later
sever
mechan
suggest
may
contribut
antivir
activ
ribavirin
includ
inhibit
viral
cap
mediat
effect
viral
guanylyltransferas
inhibit
viral
methyltransferas
virus
encod
enzym
goswami
et
al
bougi
bisaillon
bougi
bisaillon
benarroch
et
al
ii
inhibit
rnadepend
rna
polymeras
activ
ribavirin
triphosph
shown
influenza
hcv
eriksson
et
al
maag
et
al
bougi
bisaillon
iii
inhibit
viral
helicas
activ
suggest
reovirus
rankin
et
al
polioviru
rnadepend
rna
polymeras
shown
incorpor
ribavirin
opposit
cytidin
uridin
grow
rna
chain
crotti
et
al
polioviru
cultur
presenc
high
concentr
ribavirin
mm
accumul
mutat
genom
viru
grown
untreat
cultur
accumul
mutat
viral
genom
result
process
call
error
catastroph
crotti
et
al
singl
mutat
polioviru
rnadepend
rna
polymeras
gene
found
increas
enzym
fidel
render
viru
less
suscept
mutagen
effect
ribavirin
pfeiffer
kirkegaard
error
catastroph
also
propos
involv
antivir
activ
ribavirin
hantaan
viru
replic
severson
et
al
well
replic
footandmouth
diseas
viru
airaksinen
et
al
gb
viru
b
viru
lanford
et
al
remain
howev
unclear
extent
error
catastroph
deplet
intracellular
gtppool
one
propos
mechan
contribut
actual
antivir
effect
ribavirin
whether
effect
also
play
part
antivir
activ
compound
vivo
flavivirus
paramyxovirus
demonstr
gtp
pool
deplet
predomin
mechan
ribavirin
exert
antivir
activ
leyssen
et
al
flavivirus
error
catastroph
appear
contribut
vitro
antivir
activ
drug
ribavirin
first
approv
aerosol
treatment
sever
respiratori
tract
infect
children
caus
rsv
today
actual
clinic
benefit
treatment
debat
review
report
case
clinic
trial
indic
ribavirin
may
reduc
durat
mechan
ventil
may
reduc
day
hospit
addit
use
ribavirin
may
associ
decreas
longterm
incid
recurr
wheez
follow
rsv
diseas
ventr
randolph
patient
chronic
infect
hcv
ribavirin
alon
induc
either
transient
earli
declin
decreas
hcv
viral
load
combin
interferon
significantli
improv
longterm
respons
rate
precis
mechan
compound
improv
efficaci
interferon
dixit
et
al
remain
matter
debat
conflict
evid
report
regard
potenti
ribavirin
induc
error
catastroph
one
hand
increas
mutat
rate
detect
hcv
genom
isol
patient
treat
ribavirin
lutchman
et
al
pawlotski
et
al
b
ribavirininterferon
combin
therapi
schinkel
et
al
pawlotski
et
al
b
chevaliez
et
al
chevaliez
pawlotski
hand
subset
ribavirintr
hcvinfect
patient
increas
number
mutat
observ
asahina
et
al
ribavirin
use
offlabel
treatment
lassa
fever
use
howev
base
singl
publish
studi
use
histor
control
group
mccormick
et
al
intraven
administr
ribavirin
appear
efficaci
drug
given
oral
like
relat
fact
plasma
concentr
reach
follow
oral
dose
lower
treatment
lassa
fever
ribavirin
effect
given
earli
stage
cours
diseas
reduc
efficaci
note
ribavirin
given
late
stage
diseas
mccormick
et
al
schmitz
et
al
drug
also
use
postexposur
prophylaxi
publish
data
support
use
inform
use
ribavirin
treatment
lassa
fever
anoth
arenaviru
infect
argentin
hemorrhag
fever
reader
refer
articl
khan
et
al
enria
et
al
ribavirin
show
benefici
effect
placebocontrol
studi
patient
infect
hantaan
viru
hemorrhag
fever
renal
syndrom
hfr
treatment
initi
earli
cours
diseas
huggin
et
al
howev
two
doubleblind
placebocontrol
studi
patient
infect
new
world
hantaviru
hantaviru
cardio
pulmonari
syndrom
hp
drug
virtual
clinic
efficaci
chapman
et
al
collabor
antivir
studi
group
lack
activ
may
relat
phase
infect
sever
diseas
may
call
earli
intervent
see
jonsson
et
al
hp
larg
extent
immunopatholog
syndrom
thu
even
effect
antivir
may
littl
util
without
control
deleteri
host
respons
fullforc
time
patient
seek
medic
attent
ribavirin
also
use
administ
either
oral
intraven
treat
cchf
fisherhoch
et
al
mardani
et
al
bossi
et
al
describ
ergonul
evid
efficaci
limit
observ
studi
placebocontrol
studi
may
ethic
reason
imposs
perform
patient
cchf
despit
shortcom
postexposur
prophylaxi
treatment
ribavirin
everi
stage
diseas
recommend
ribavirin
also
use
without
much
success
firstlineofdef
emerg
virus
nipah
viru
sarscoronaviru
chong
et
al
stockman
et
al
final
ribavirin
effect
treatment
filoviru
infect
review
bausch
et
al
treatment
japanes
enceph
yellow
fever
flavivir
infect
see
articl
gould
et
al
monath
increas
oral
bioavail
ribavirin
decreas
sideeffect
doselimit
hemolyt
anemia
variou
prodrug
ribavirin
develop
viramidin
fig
amin
prodrug
ribavirin
deamin
vivo
adenosin
deaminas
wu
et
al
drug
follow
absorpt
rapidli
convert
ribavirin
activ
viramidin
influenza
viru
replic
compar
ribavirin
sidwel
et
al
viramidin
develop
treatment
hcv
infect
sever
analogu
ribavirin
levovirin
mizoribin
studi
levovirin
fig
lanalogu
ribavirin
undergo
phosphoryl
antivir
activ
vitro
propos
levovirin
possess
akin
ribavirin
immunomodulatori
activ
tam
et
al
tam
et
al
clinic
studi
levovirin
hcvinfect
patient
unsuccess
suggest
immunomodulatori
activ
levovirin
suffici
result
clinic
efficaci
levovirin
develop
fang
et
al
mizoribin
fig
hydroxyl
analogu
ribavirin
inhibit
akin
ribavirin
cellular
imp
dehydrogenas
molecul
develop
immunosuppress
agent
gan
et
al
rather
antivir
agent
although
antivir
activ
combin
agent
report
saijo
et
al
naka
et
al
yanagida
et
al
stuyver
et
al
potent
revers
uncompeti
tive
imp
dehydrogenas
inhibitor
imepodib
fig
structur
unrel
inhibitor
enzym
develop
shown
exhibit
vitro
antivir
activ
superior
ribavirin
howev
compound
develop
markland
et
al
although
ribavirin
exert
broadspectrum
activ
vitro
clinic
use
discuss
limit
viral
infect
mechan
ribavirin
inhibit
viral
replic
vari
viru
studi
consid
select
gtp
deplet
error
catastroph
etc
design
safe
potent
analogu
ribavirin
broadspectrum
activ
use
treatment
varieti
rna
viru
infect
therefor
like
difficult
achiev
eicar
analogu
ribavirin
fig
shown
vitro
roughli
potent
inhibit
replic
variou
rna
virus
leyssen
et
al
howev
improv
activ
came
price
concomit
increas
toxic
explain
fact
metabolit
eicar
also
potent
ribavirin
monophosph
inhibit
imp
dehydrogenas
balzarini
et
al
initi
interact
viru
host
cell
repres
attract
target
therapeut
intervent
discuss
briefli
possibl
approach
inhibit
earli
event
replic
cycl
rna
virus
includ
picorna
coronaarenaand
paramyxovirus
strategi
inhibit
entri
uptak
report
attach
picornavirus
occur
bind
host
cell
receptor
canyon
situat
around
vertex
capsid
bind
receptor
believ
trigger
also
uncoat
process
bind
specif
molecul
pocket
immedi
underneath
floor
canyon
result
increas
protein
rigid
stabil
particl
manner
uncoat
proceed
review
de
palma
et
al
submit
public
numer
compound
identifi
inhibit
picornaviru
replic
specif
interact
pocket
two
compound
bind
pocket
pleconaril
fig
pirodavir
fig
evalu
clinic
set
develop
mani
envelop
virus
carri
carbohydratecontain
protein
surfac
glycoprotein
key
infect
process
mediat
bind
andor
uptak
thu
attract
target
develop
novel
antivir
therapi
recent
carbohydratebind
agent
shown
exert
vitro
antivir
activ
toward
number
virus
includ
coronavirus
van
der
meer
et
al
balzarini
b
human
monoclon
antibodi
palivizumab
synagi
target
rsv
fusion
protein
johnson
et
al
approv
prophylact
therapi
rsv
infect
administ
highrisk
pediatr
patient
preclin
develop
fusion
inhibitor
fig
dougla
et
al
dougla
et
al
fig
dougla
et
al
interact
rsv
f
polyprotein
albeit
differ
site
indic
resist
mutat
select
presenc
inhibitor
peptid
deriv
f
protein
hrn
hrc
region
interfer
fusion
intermedi
f
candid
molecul
imped
viru
entri
fusion
peptid
deriv
human
parainfluenza
hendra
viru
shown
inhibit
hendra
viru
replic
vitro
porotto
et
al
similar
strategi
would
also
amen
coronavirus
yan
et
al
abil
peptid
interfer
class
fusion
process
led
creation
clinic
effect
peptid
inhibitor
fusion
enfuvirtid
fig
relat
molecul
dwyer
et
al
efficaci
therapi
infect
support
concept
design
effect
therapi
base
understand
mechan
viral
fusion
use
peptid
antivir
recent
recombin
fusion
protein
compos
catalyt
domain
neuraminidas
sialidas
deriv
actinomyc
viscosu
fuse
cellsurfaceanchor
sequenc
report
novel
broadspectrum
inhibitor
influenza
viru
replic
fusion
protein
appli
aerosol
remov
sialic
acid
influenza
receptor
airway
epithelium
sialidas
fusion
protein
fludas
report
subnanomolar
concentr
inhibit
human
avian
influenza
viru
replic
signific
vivo
efficaci
note
prophylact
therapeut
approach
experiment
influenza
viru
infect
anim
malakhov
et
al
compound
advanc
preclin
develop
nexbio
highthroughput
screen
effort
result
identif
potent
broadspectrum
inhibitor
arenaviru
entri
bolken
et
al
discuss
picornavirus
inhibit
viral
uncoat
result
inhibit
viral
replic
picornavirus
fig
structur
enfuvirtid
uncoat
process
link
receptor
bind
envelop
virus
uncoat
process
take
place
viru
adsorpt
viruscel
fusion
process
perhap
best
known
antivir
uncoat
inhibitor
adamantan
amin
e
deriv
select
inhibit
uncoat
process
influenza
virus
see
cap
viral
rna
intern
ribosom
entri
site
ire
mediat
transcript
viral
rna
may
also
seem
attract
larg
unexplor
target
antivir
therapi
follow
enzym
play
crucial
role
cap
machineri
omethyltransferas
guanylyltransferas
rnatriphosphatas
egloff
et
al
egloff
et
al
benarroch
et
al
potenti
methyl
transferas
drug
target
flavivirus
recent
demonstr
luzhkov
et
al
inhibit
rna
viru
replic
target
host
sahhydrolas
discuss
section
variou
inhibitor
hcv
ire
synthes
none
far
proven
suffici
potent
warrant
develop
jubin
mani
rna
virus
encod
one
proteas
perhap
best
character
flavivirida
hcv
flavivirus
picornavirida
although
hcv
discuss
review
import
mention
success
develop
highli
potent
select
inhibitor
hcv
serin
proteas
lamarr
colleag
first
develop
potent
hcv
inhibitor
fig
demonstr
efficaci
drug
patient
chronic
infect
hcv
paus
et
al
cardiotox
experiment
model
develop
compound
discontinu
howev
hcv
proteas
inhibitor
develop
excel
efficaci
demonstr
clinic
set
advanc
fig
de
francesco
migliaccio
foresti
et
al
crystal
structur
dengu
viru
proteas
solv
murthi
et
al
first
inhibitor
enzym
report
ganesh
et
al
prevent
andor
treatment
rhinoviru
infect
inhibitor
human
rhinoviru
hrv
proteas
extens
investig
ruprintrivir
fig
irrevers
proteas
inhibitor
upon
intranas
administr
human
volunt
appear
safe
well
toler
experiment
induc
rhinoviru
cold
healthi
volunt
prophylaxi
drug
reduc
proport
subject
posit
viral
cultur
reduc
frequenc
cold
binford
et
al
analogu
ruprintrivir
excel
oral
bioavail
develop
compound
appear
safe
phase
studi
progress
toward
clinic
develop
patick
crystal
structur
main
proteas
mpro
human
coronaviru
determin
reveal
remark
degre
conserv
substratebind
site
picornaviru
proteas
molecular
model
suggest
ruprintrivir
analogu
may
modifi
make
effici
inhibitor
coronaviru
sarscoronaviru
replic
yang
et
al
yang
et
al
numer
select
inhibitor
hcv
replic
identifi
target
viral
rnadepend
rna
polymeras
rdrp
case
hiv
revers
transcriptas
compound
larg
classifi
nucleosid
nonnucleosid
inhibitor
nucleosid
analogu
need
phosphoryl
triphosph
metabolit
inhibit
function
enzym
activ
site
nonnucleosid
analogu
act
alloster
site
inhibitor
sever
nucleosid
nonnucleosid
inhibitor
clinic
develop
fig
structur
ruprintrivir
ment
treatment
infect
hcv
de
francesco
migliaccio
nucleosid
hcv
inhibitor
cmethylcytidin
fig
fig
relat
cmethyl
nucleosid
exert
broadspectrum
activ
singl
plusstrand
rna
virus
includ
activ
picornaviru
footandmouth
diseas
viru
gori
et
al
nucleosid
inhibitor
hcv
replic
azidocytidin
fig
drug
develop
roch
sole
activ
hcv
klumpp
et
al
unpublish
find
hcv
also
possibl
develop
highli
select
nonnucleosid
inhibitor
polymeras
rna
virus
demonstr
exampl
pestivirus
baginski
et
al
paeshuys
et
al
paeshuys
et
al
thu
develop
potent
nonnucleosid
inhibitor
relat
virus
member
flavivirida
highli
pathogen
agent
cover
issu
may
well
feasibl
influenza
viru
rna
polymeras
consist
complex
three
virusencod
enzym
pa
addit
rna
replic
activ
also
contain
endonucleas
activ
ensur
cap
snatch
initi
transcript
subsequ
translat
process
deng
et
al
compound
report
target
influenza
polymeras
replicas
like
inhibitor
shown
inhibit
revers
transcriptas
rnadepend
dna
polymeras
hiv
rna
replicas
hcv
influenza
replicas
inhibitor
principl
also
divid
two
class
nucleosid
nonnucleosid
year
ago
fluoroguanosin
fig
describ
inhibitor
influenza
viru
transcript
although
studi
capac
tisdal
et
al
recent
substitut
pyrazin
fig
report
potent
vitro
activ
influenza
b
c
furuta
et
al
furuta
et
al
polymeras
inhibitor
expect
resist
profil
overlap
neuraminidas
inhibitor
accord
compar
studi
would
even
potent
oseltamivir
increas
multipl
infect
vitro
use
higher
viru
challeng
dose
vivo
takahashi
et
al
avian
influenza
found
less
effect
oseltamivir
cell
cultur
effect
ribavirin
prove
also
effect
administ
oral
lethal
avian
influenza
viru
infect
mice
postul
convert
intracellularli
ribonucleotid
monophosph
rmp
phosphoribosyl
transferas
upon
phosphoryl
triphosph
rtp
would
inhibit
influenza
viru
rna
polymeras
gtpcompetit
manner
furuta
et
al
fig
unlik
ribavirin
monophosph
rmp
significantli
inhibit
imp
dehydrogenas
indic
may
owe
antiinfluenza
viru
activ
mainli
exclus
inhibit
influenza
viru
rna
polymeras
cap
snatch
cap
scaveng
endonucleas
activ
associ
influenza
polymeras
complex
may
attract
target
drug
therapi
number
molecul
shown
inhibit
influenza
endonucleas
activ
flutimid
fig
isol
extract
fungal
speci
delitschia
confertaspora
inhibit
capdepend
endonucleas
activ
influenza
viru
b
strain
replic
cell
cultur
tomassini
et
al
recent
antiinfluenza
inhibitor
also
accredit
vitro
vivo
activ
panel
arenavirus
pichind
bunyavirus
punta
toro
gowen
et
al
gener
activ
ribavirin
reflect
substanti
greater
therapeut
index
suggest
may
viabl
altern
treatment
lifethreaten
infect
bunyaor
arenavirus
gowen
et
al
may
assum
mechan
inhibit
replic
bunyaand
arenavirus
similar
mechan
fig
intracellular
metabol
mechan
action
influenza
viru
would
first
convert
ribonucleotid
rmp
would
subsequ
convert
triphosph
rtp
would
inhibit
influenza
viru
rna
polymeras
competit
gtp
furuta
et
al
presum
inhibit
influenza
replic
inhibit
viral
polymeras
almost
rna
virus
encod
helicasentpas
respons
unwind
doublestrand
rna
form
replic
helicas
may
repres
attract
target
therapi
substanti
effort
identifi
inhibitor
hcv
helicasentpas
inhibitor
function
describ
far
develop
frick
borowski
et
al
ujjinamatada
et
al
recent
identifi
class
thiazolobenzimidazol
fig
potent
inhibitor
replic
variou
enterovirus
mechanist
studi
indic
compound
target
picornaviru
gene
product
predict
helicasentpas
coxsacki
viru
express
shown
function
ntpase
activ
howev
inhibit
class
compound
de
palma
et
al
accept
public
nevertheless
unpublish
data
suggest
thiazolibenzimidazol
might
interfer
assemblyfunct
viral
helicas
helicas
consid
valuabl
yet
larg
unexplor
target
antivir
therapi
recent
novel
inhibitor
rsv
replic
identifi
benzodiazepin
fig
first
new
class
rsv
inhibitor
current
phase
ii
clinic
trial
appear
target
viral
nucleocapsid
n
protein
chapman
et
al
compound
may
possibl
prevent
assembl
viru
particl
repres
one
promis
candid
drug
date
treatment
rsv
infect
human
essenti
step
viral
life
cycl
releas
new
progeni
virion
infect
cell
discuss
section
process
extens
studi
influenza
viru
result
identif
neuraminidas
inhibitor
mani
rna
virus
littl
inform
precis
molecular
event
lead
releas
progeni
virion
quit
number
antivir
agent
report
target
cellular
factor
may
prevent
interact
cellular
factor
replic
machineri
viru
other
may
influenc
host
cell
metabol
way
effici
viral
replic
prevent
variou
host
cell
factor
play
key
role
effici
replic
rna
virus
discov
immunosuppress
agent
cyclosporin
inhibit
hcv
replic
vitro
nakagawa
et
al
propos
effect
mediat
blockad
cyclophilin
nakagawa
et
al
cyclosporin
fig
would
suppress
hcv
replic
level
hcv
rna
polymeras
watashi
et
al
specif
cyclosporin
would
block
abil
peptidylprolyl
cistran
isomeras
ppias
cyclophilin
b
cypb
bind
rna
replicas
thu
inhibit
function
rna
replicas
rice
report
fig
nonimmunosuppress
analogu
csa
much
potent
inhibitor
hcv
replic
csa
paeshuys
recent
data
indic
mechan
action
cyclosporin
may
differ
propos
interact
coelmont
et
al
current
phase
ii
clinic
studi
treatment
hcv
infect
clinic
efficaci
treatment
hcv
infect
support
concept
molecul
prevent
crucial
interact
viral
cellular
factor
may
interest
antivir
agent
advantag
approach
also
shown
may
make
antivir
resist
develop
difficult
endoplasm
reticulum
er
alphaglucosidas
inhibitor
block
trim
step
nlink
glycosyl
shown
imped
product
sever
erbud
virus
includ
flaviand
pestivirus
well
hcv
wu
et
al
lethal
mous
model
japanes
enceph
oral
deliveri
nnonyldeoxynojirimycin
fig
reduc
mortal
rate
wu
et
al
sinc
viral
replic
predominantli
reli
build
block
present
host
cell
appar
interf
suppli
slow
halt
product
progeni
virus
howev
antivir
drug
target
nucleosid
metabol
host
cell
result
inhibit
viral
replic
also
endow
cytotox
andor
cytostat
effect
thu
although
compound
may
prove
antivir
activ
lack
select
discuss
earlier
inhibit
imp
dehydrogenas
result
deplet
intracellular
gtppool
contribut
antivir
activ
ribavirin
structur
relat
molecul
viramidin
eicar
structur
unrel
compound
mycophenol
acid
fig
put
target
coenzym
nad
rather
apoenzym
ribavirin
congen
target
ever
sinc
sadenosylhomocystein
hydrolas
sah
recogn
pharmacolog
target
antivir
agent
montgomeri
et
al
increas
number
adeno
sine
acycl
adenosin
carbocycl
adenosin
analogu
describ
potent
sah
hydrolas
inhibitor
endow
broadspectrum
antivir
activ
de
clercq
antivir
activ
spectrum
sah
hydrolas
inhibitor
rna
virus
includ
rhabdo
filo
arena
paramyxo
reo
retrovirus
among
potent
sah
hydrolas
inhibitor
antivir
agent
rank
carbocycl
cc
ado
fig
neplanocin
fig
fig
deriv
carbocycl
adenosin
cado
aristeromycin
fig
ralkyl
methyl
deriv
neplanocin
compound
particularli
activ
rhabdovirus
proven
effect
filovirus
ebola
viru
huggin
et
al
fact
administ
singl
dose
mgkg
first
second
day
ebola
zair
viru
infect
mice
reduc
peak
viremia
compar
mocktreat
control
anim
surviv
bray
et
al
protect
effect
accompani
probabl
mediat
product
high
concentr
ebola
virusinfect
mice
bray
et
al
could
postul
block
cap
nascent
viral
rna
strand
matur
depend
methyl
fig
prevent
dissoci
strand
viral
rna
genom
therebi
lead
accumul
replic
intermedi
replic
intermedi
contain
doublestrand
rna
stretch
could
accord
concept
propos
mani
year
ago
carter
de
clercq
implic
highlevel
product
interferon
pyrazofurin
fig
prototyp
omp
decarboxylas
inhibitor
activ
rna
virus
picornavirus
polioviru
coxsacki
togavirus
sindbi
rna
virus
paramyxovirus
measl
rsv
orthomyxovirus
fig
mechan
action
sadenosylhomocystein
hydrolas
sah
inhibitor
sah
productinhibitor
methyl
reaction
includ
requir
matur
cap
viral
mrna
hydrolysi
sah
sah
hydrolas
prevent
accumul
sah
would
otherwis
lead
inhibit
samdepend
methyl
reaction
influenza
b
c
rhabdovirus
vesicular
stomat
viru
arenavirus
junin
tacarib
de
clercq
shigeta
et
al
also
paramyxovirus
rsv
kawana
et
al
measl
viru
hosoya
et
al
report
sensit
inhibit
pyrazofurin
recent
also
proven
case
nipah
viru
anoth
paramyxoviru
georgescourbot
et
al
act
omp
decarboxylas
inhibitor
pyrazofurin
must
first
convert
cellular
kinas
monophosph
fig
anoth
compound
known
interfer
convers
omp
ump
fig
requir
intracellular
phosphoryl
compound
much
known
antivir
activ
spectrum
rada
dragun
howev
similar
pyrazofurin
like
pyrazofurin
found
effect
nipah
viru
georgescourbot
et
al
carbocycl
analogu
normal
nucleosid
cytidin
cyclopentylcytosin
ccyd
carbodin
fig
cyclopentenylcytosin
cecyd
fig
consid
potenti
antivir
antitumor
agent
ccyd
first
describ
antiinfluenza
viru
agent
shannon
et
al
also
shown
activ
dna
virus
poxvirus
vaccinia
rna
virus
togavirus
sindbi
semliki
forest
rna
virus
orthomyxovirus
influenza
paramyxovirus
parainfluenza
measl
rhab
mechan
action
omp
decarboxylas
inhibitor
ctp
synthetas
inhibitor
omp
decarboxylas
inhibitor
pyrazofurin
need
phosphoryl
monophosph
abl
interact
omp
decarboxylas
ctp
synthetas
inhibitor
ccyd
cecyd
need
phosphoryl
triphosph
abl
interact
ctp
synthetas
dovirus
vesicular
stomat
dsrna
virus
reoviru
cecyd
potent
antivir
agent
counterpart
ccyd
addit
also
prove
activ
picornavirus
polioviru
coxsacki
b
rhinoviru
herpesvirus
de
clercq
et
al
antivir
activ
spectrum
cecyd
extend
bunyavirus
punta
toro
flavivirus
japanes
enceph
arenavirus
junin
tacarib
marquez
et
al
andrei
de
clercq
antitumor
antivir
effect
ccyd
cecyd
put
target
assum
ctp
synthetas
enzym
catalys
convers
utp
ctp
final
step
de
novo
pyrimidin
biosynthet
pathway
fact
antivir
cytotox
effect
ccyd
cecyd
readili
revers
cytidin
lesser
extent
uridin
nucleosid
deoxythymidin
deoxycytidin
support
hypothesi
mani
target
exist
select
inhibit
replic
rna
virus
discuss
paper
mani
potenti
interest
target
remain
unexplor
concert
effort
dedic
laboratori
act
intern
network
vizier
network
describ
coutard
et
al
issu
studi
structur
genom
enzym
involv
rna
viru
replic
may
instrument
identifi
novel
antivir
strategi
inhibit
rna
viru
resplic
exampl
may
assum
strictli
regul
nuclear
import
eight
influenza
rna
segment
encapsid
one
singl
copi
rna
segment
progeni
viral
particl
may
repres
potenti
target
therapeut
intervent
greber
fornerod
although
technic
feasibl
develop
drug
treatment
variou
famili
genera
rna
virus
exampl
flavivirus
orthomyxovirus
paramyxovirus
picornavirus
etc
pharmaceut
industri
unlik
develop
antivir
diseas
market
small
uncertain
ideal
antivir
drug
develop
exert
broadspectrum
antirna
viru
activ
fact
influenza
polymeras
inhibitor
also
inhibit
replic
rna
virus
gowen
et
al
cmethyl
nucleosid
analogu
inhibitor
hcv
rdrp
inhibit
also
replic
variou
ssrna
virus
suggest
nucleosid
polymeras
inhibitor
may
like
broadspectrum
antivir
drug
candid
drug
licens
treatment
frequent
infect
influenza
hcv
could
eventu
use
offlabel
compassion
basi
treatment
import
less
common
infect
highli
pathogen
rna
virus
